" class="no-js "lang="en-US"> Jan Thirkettle - Medtech Alert
Monday, June 16, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Jan Thirkettle

Jan Thirkettle

About Jan Thirkettle

Jan has more than 20 years’ experience of building cross functional teams to drive delivery of innovative technologies. He has built platforms and played a leadership role in the commercialisation of therapeutics across small molecule, biopharmaceutical and gene therapy modalities. Jan joined Transine Therapeutics from Freeline Therapeutics where he was start-up CEO then Chief Development Officer overseeing deployment of a novel AAV platform and a rapidly growing clinical-phase portfolio. Prior to this Jan spent close to 20 years at GSK in multiple senior roles spanning from Discovery to Manufacturing environments, latterly overseeing the establishment of the Cell & Gene Therapy platform unit where he played a pivotal role in the commercialisation of Strimvelis, the first ex-vivo gene therapy to receive an EU Marketing Authorisation Application. He has served on multiple advisory boards in the CMC and regulatory space, playing a significant role in the shaping of the Cell and Gene therapy field.  Jan holds an MA in Chemistry and a PDhil. in Biological Chemistry from Oxford University.